Dr. Hammer is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 East Medical Center Dr
1ST floor Cancer Geriatrics Center
Ann Arbor, MI 48109Phone+1 734-763-4876
Summary
- Gary D. Hammer, M.D., Ph.D. is Professor in Departments of Internal Medicine (MEND), Cell & Developmental Biology, and Molecular & Integrative Physiology. He currently serves as Director of Endocrine Oncology Program in Rogel Cancer Center where he holds the Millie Schembechler Professorship in Adrenal Cancer. He is past Director of Center for Organogenesis: Stem Cells & Regenerative Medicine. He has brokered the recent renaissance of the current Michigan team of adrenal scientists that includes a who’s who in the study of adrenal disease. He received the UofM Jerome Conn Award for Outstanding Research in Internal Medicine, the Endocrine Society Edwin B. Astwood Award for Outstanding Research and is a member of ASCI and AAP. He has served in numerous leadership roles at UofM and in the public and private sectors including recent tenure on Board of Scientific Advisors for NCI. He is the editor of four textbooks including Pathophysiology of Disease: An Introduction to Clinical Medicine (McGraw Hilll), and the Adrenal Section Editor for Degroot’s Endocrinology (Elsevier). He has served in numerous capacities for the world’s largest endocrine organization, the Endocrine Society including his most recent role as President of the Society (2020-2021). An Advisor to the Congressional H.E.L.P. committee - he co-authored the 21st Century Cancer ALERT (Access to Life-Saving Early detection, Research and Treatment) Act’’ introduced in Congress in 2009. He has been catalyst for the formation of two international cooperative groups, most recently the A5 (American Australian Asian Adrenal Alliance) that leverages collaboration to secure projects from Pharma and funding agencies across the spectrum of adrenal diseases. He is a co- founder of two companies - MILLENDO and SLING THERAPEUTICS that focus on rare endocrine diseases.
Education & Training
- University of California (San Francisco)Fellowship, Endocrinology, Diabetes, and Metabolism, 1994 - 1998
- University of California (San Francisco)Residency, Internal Medicine, 1992 - 1994
- Tufts University Sackler School of Graduate Biomedical SciencesPhD, 1985 - 1992
- Tufts University School of MedicineClass of 1992
- University of VermontBA, Psychology, Magna Cum Laude, 1981 - 1985
Certifications & Licensure
- CA State Medical License 1993 - Present
- MI State Medical License 2000 - 2026
- American Board of Internal Medicine Endocrinology, Diabetes and Metabolism
Awards, Honors, & Recognition
- Elected Member American Association of Physicians, 2012
- The One Hundred, Inductee Massachusetts General Hospital Cancer Center, 2014
- America's Top Doctors Castle Connolly, 2011-2014
- Join now to see all
Clinical Trials
- IMC-A12 With Mitotane vs Mitotane Alone in Recurrent, Metastatic, or Primary ACC That Cannot Be Removed by Surgery Start of enrollment: 2008 Dec 01
Publications & Presentations
PubMed
- 1816 citationsOncogenic Signaling Pathways in The Cancer Genome AtlasFrancisco Sanchez-Vega, Marco Mina, Joshua Armenia, Walid K. Chatila, Augustin Luna
Cell. 2018-04-05 - 869 citationsDiagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline.Stefan R. Bornstein, Bruno Allolio, Wiebke Arlt, Andreas Barthel, Andrew C. Don-Wauchope
The Journal of Clinical Endocrinology and Metabolism. 2016-02-01 - 83 citationsComprehensive Pan-Genomic Characterization of Adrenocortical Carcinoma.Siyuan Zheng, Andrew D Cherniack, Ninad Dewal, Richard A Moffitt, Ludmila Danilova
Cancer Cell. 2016-05-09
Journal Articles
- Withanolides Are Potent Novel Targeted Therapeutic Agents against Adrenocortical CarcinomasSubramanian C, Zhang H, Gallagher R, Hammer G, Timmermann B. and Cohen M, World Journal of Surgery, 6/1/2014
- Abiraterone Acetate Added to Physiologic Hydrocortisone and Fludrocortisone Acetate Normalizes Androgen Excess in Adult Women With Classic 21-Hydroxylase DeficiencyAuchus RJ, Buschur EO, Chang AY, Hammer GD, Ramm C, Madrigal M, Wang G, Gonzalez M, Xu S, Smit JW, Jiao J and Yu MK, Journal of Clinical Endocrinology and Metabolism, 4/29/2014
- Wnt-Signaling Inhibits Adrenal Steroidogenesis by Cell-Autonomous and Non-Ceell Autonomous MechanismsWalczak EM, Kuick,R, Finco I, Bohin, N, Hrycaj S, Wellick, D and Hammer G, Molecular Endocrinology, 1/1/2014
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Phase 1 Study of ATR-101 in Adrenocortical Carcinoma (ACC): ATR-101-001Naing A, Habra M, Chugh R, Ijzerman M, Hesseltine E, Worden F, Phillips M, Smith D, The American Society of Clinical Oncology Abstracts, 1/1/2014
- Adjuvant Radiotherapy Improves Local Control after Surgical Resection in Patients with Localized Adrenocortical Carcinoma: A Retrospective Cohort StudySabolch A, Else T, Jackson W, Griffith K, Miller B, Worden F, Williams A, Hammer GD, Jolly S, The Department of Radiation Oncology. University of Michigan, 1/1/2014
- CDK7 Regulates Adrenal Development and Steroidogenesis in MiceXing Y, and Hammer GD, The Endocrine Society Annual Meeting Abstracts, 1/1/2014
- Join now to see all
Lectures
- Career Development Workshop - Communications Skills Lab: How to Communicate Your Work to Media and Lay PublicENDO 2019 - New Orleans, LA - 3/23/2019
- Early Career ForumENDO 2019 - New Orleans, LA - 3/22/2019
- 2019 Latin American Leadership AcademyENDO 2019 - New Orleans, LA - 3/22/2019
- Join now to see all
Other
- Adrenal CancerThe Group Room Talk Radio 154
1/1/2007 - Treatment of adrenocortical carcinomaHammer GD, Lacroix A
http://www.uptodate.com/contents/treatment-of-adrenocortical-carcinoma
UpToDate, Wolters Kluwer Health - 2013-02-01
Press Mentions
- Gary D Hammer on the Improvement of Patient Care in Endocrine NeoplasiaDecember 23rd, 2019
- Michigan Medicine's Division of Metabolism, Endocrinology and Diabetes Showcases New Research at Endocrine Society's ENDO 2018March 17th, 2018
- Adrenal Disorders Experts Address Rare Conditions and Their Treatment at American Association of Clinical Endocrinologists Scientific and Clinical CongressMay 5th, 2017
- Join now to see all
Grant Support
- Wnt-Responsive Adrenocortical Cells In Organ Maintenance And CancerNational Cancer Institute2010–2012
- Mechanisms Of Adrenal DifferentiationNational Institute Of Diabetes And Digestive And Kidney Diseases2004–2012
- Mechanisms Of Adrenal Cortex Growth/DifferentiationNational Institute Of Diabetes And Digestive And Kidney Diseases2000
- Orphan Nuclear Receptors In Development And DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases1999–2000
- Orphan Nuclear Receptors In Development And DiseaseNational Institute Of Diabetes And Digestive And Kidney Diseases1996–1999
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: